Filter your results
- 3
- 1
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 4
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre studyERJ Open Research, 2023, 9 (1), pp.00199-2022. ⟨10.1183/23120541.00199-2022⟩
Journal articles
hal-04066597v1
|
||
|
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesRespirology, 2022, 27 (4), pp.294-300. ⟨10.1111/resp.14231⟩
Journal articles
hal-03629139v1
|
||
|
Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countriesBMC Pulmonary Medicine, 2017, 17 (1), pp.124. ⟨10.1186/s12890-017-0468-5⟩
Journal articles
hal-01616061v1
|
||
Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trialEuropean Respiratory Journal, 2020, 56, ⟨10.1183/13993003.congress-2020.4577⟩
Journal articles
hal-03162087v1
|